FTSE MIB
34.389,59 +25,84 (+0,08%) Dow Jones
38.503,69 +263,71 (+0,69%) Nasdaq
15.696,64 +245,33 (+1,59%) Nikkei 225
38.460,08 +907,92 (+2,42%) Petrolio
82,98 -0,38 (-0,46%) Bitcoin EUR
62.300,84 +446,33 (+0,72%)
Emergent BioSolutions Inc. (EBS)
Preborsa:
| Chiusura precedente | 2,1600 |
| Aperto | 2,1500 |
| Denaro | 0,0000 x 2200 |
| Lettera | 0,0000 x 4000 |
| Min-Max giorno | 2,1300 - 2,3600 |
| Intervallo di 52 settimane | 1,4200 - 10,8800 |
| Volume | |
| Media Volume | 3.039.359 |
| Capitalizzazione | 119,975M |
| Beta (5 anni mensile) | 1,19 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -14,8500 |
| Prossima data utili | 01 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 5,00 |
GlobeNewswireEmergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors
GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent’s 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. “Neal and Don bring unique and extensive expertise to Emergent as the company defines
GlobeNewswireEmergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
NARCAN® Nasal Spray Carton, Two Doses This media asset is free for editorial broadcast, print, online and radio use. It is restricted for use for other purposes. Emergent requests acknowledgement of these images with a "Courtesy of Emergent" statement below each image. NARCAN® Nasal Spray In Use This media asset is free for editorial broadcast, print, online and radio use. It is restricted for use for other purposes. Emergent requests acknowledgement of these images with a "Courtesy of Emergent"
GlobeNewswireEmergent BioSolutions Reports Financial Results for Second Quarter 2023
Reports Q2 2023 total revenues of $338M, above the prior guidance range, net loss of $261M and adjusted EBITDA of $56MUpdates FY 2023 guidance and provides initial Q3 2023 forecast for total revenues GAITHERSBURG, Md., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the second quarter ended June 30, 2023. It also announced strategic steps to reduce investment in and de-emphasize focus on growth in its CDMO business. “Emergent has achi
